Terminated PHASE3 INTERVENTIONAL 3-arm NCT01684345

Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis (EYEGUARD™-A)

A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis

Sponsor: Institut de Recherches Internationales Servier

Conditions Uveitis

Interventions Dose 1 gevokizumab Dose 2 gevokizumab Placebo

Updated 7 times since 2017 Last updated: Apr 7, 2016 Started: Aug 31, 2012 Primary completion: Feb 29, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from Institut de Recherches Internationales Servier

See all terminations from Institut de Recherches Internationales Servier

Other Uveitis trials with similar outcome

Browse all Uveitis trials

A PHASE3 clinical study on Uveitis, this trial is terminated or withdrawn. The trial is conducted by Institut de Recherches Internationales Servier and has accumulated 7 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE3
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Terminated PHASE3
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE3

First recorded

Aug 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Institut de Recherches Internationales Servier
XOMA (US) LLC

Data source: XOMA (US) LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ankara, Turkey (Türkiye) , Ashland, United States , Atlanta, United States , Austin, United States , Baltimore, United States , Barcelona, Spain , Beachwood, United States , Beijing, China , Belmont, United States , Belo Horizonte, Minas Gerais, Brazil and 106 more locations